{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:35Z","timestamp":1761171875517,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":3582,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.farma.2011.05.002","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T02:52:22Z","timestamp":1323312742000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efectividad y seguridad del r\u00e9gimen FLAG-IDA en leucemias agudas resistentes o recidivantes"],"prefix":"10.1016","volume":"36","author":[{"given":"L.","family":"Dom\u00ednguez Sen\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.","family":"Rodr\u00edguez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"Garrido Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"S\u00e1nchez Arg\u00e1iz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mart\u00edn Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2011.05.002_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148532","article-title":"Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia","volume":"9","author":"Estey","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.farma.2011.05.002_bib0010","first-page":"278","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid and \/or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed acute myeloid leukaemia and myelodysplastic syndrome","volume":"93","author":"Estay","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.farma.2011.05.002_bib0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"Estey","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2011.05.002_bib0020","first-page":"1842","article-title":"FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of \u2018poor risk\u2019 acute myeloid leukemias","volume":"8","author":"Visani","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.farma.2011.05.002_bib0025","first-page":"513","article-title":"High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.farma.2011.05.002_bib0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.bmt.1701521","article-title":"FLAG-idaraubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission","volume":"22","author":"Deane","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.farma.2011.05.002_bib0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2141.1998.00836.x","article-title":"IDA-Flag (idarubicin,fludarabine, cytarabine, G-CSF), an effective remission - induction therapy for poor-prognosis AMLof childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a Phase- II trial","volume":"102","author":"Fleischhack","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0045","first-page":"13","article-title":"Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes","volume":"86","author":"Ferrara","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.farma.2011.05.002_bib0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002770050541","article-title":"Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML","volume":"78","author":"Steinmetz","year":"1999","journal-title":"Ann Haematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0055","first-page":"34","article-title":"Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells","volume":"329","author":"Gandhi","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.farma.2011.05.002_bib0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2011.05.002_bib0065","first-page":"826","article-title":"Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro","volume":"4","author":"Tafuri","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.farma.2011.05.002_bib0070","first-page":"2076","article-title":"Fludarabine+Ara- C+G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells","volume":"8","author":"Tosi","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.farma.2011.05.002_bib0075","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid keukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.farma.2011.05.002_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7326\/0003-4819-115-1-13","article-title":"Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission","volume":"115","author":"Horowitz","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.farma.2011.05.002_bib0085","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.1090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.farma.2011.05.002_bib0090","unstructured":"Subir\u00e0 M, Batlle M, Besses R, Rodr\u00edguez L, Urbano-Ispiz\u00faa A. Pautas de quimioterapia en hemopat\u00edas malignas. 4.a ed. FEHH\/PETHEMA; 2007."},{"key":"10.1016\/j.farma.2011.05.002_bib0095","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"International working gro up for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2011.05.002_bib0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1468-0734.2002.00058.x","article-title":"Acute myeloid leukemia: treatment of adults under 60 years","volume":"6","author":"Burnett","year":"2002","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2141.2003.04728.x","article-title":"Fludarabine cytosine arabinoside, granulocyte colony factor with or with out idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes","volume":"124","author":"Virchis","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-003-0624-2","article-title":"FLAGIda in the treatment of refractory\/relapsed acute myeloid leukemia: single centre experience","volume":"82","author":"Pastore","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0115","first-page":"482","article-title":"Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients","volume":"21","author":"Clavio","year":"2002","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.farma.2011.05.002_bib0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/10428190109057929","article-title":"First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia","volume":"40","author":"Clavio","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.farma.2011.05.002_bib0125","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtozumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.farma.2011.05.002_bib0130","first-page":"198","article-title":"Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia","volume":"42","author":"Yalman","year":"2000","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.farma.2011.05.002_bib0135","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.leu.2401406","article-title":"Early allogeneic transplantation for refractory and relapsed acute leukemia following remission induction with FLAG","volume":"13","author":"Byrne","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.farma.2011.05.002_bib0140","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1989.7.8.1071","article-title":"Response to salvage therapy and survival after relapse in acute myelogenous leukemia","volume":"7","author":"Keating","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2011.05.002_bib0145","first-page":"196","article-title":"Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group","volume":"7","author":"Carella","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.farma.2011.05.002_bib0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002770050148","article-title":"Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.","volume":"72","author":"De Witte","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1016\/j.farma.2011.05.002_bib0155","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/oxfordjournals.annonc.a010796","article-title":"Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience","volume":"7","author":"Vignetti","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2011.05.002_bib0160","first-page":"226","article-title":"Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol","volume":"84","author":"Martino","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.farma.2011.05.002_bib0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0145-2126(99)00087-9","article-title":"A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study","volume":"23","author":"Karanes","year":"1999","journal-title":"Leuk Res"},{"key":"10.1016\/j.farma.2011.05.002_bib0170","first-page":"505","article-title":"Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial","volume":"84","author":"Martino","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.farma.2011.05.002_bib0175","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.farma.2011.05.002_bib0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0145-2126(99)00078-8","article-title":"Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine","volume":"23","author":"Raanani","year":"1999","journal-title":"Leuk Res"},{"key":"10.1016\/j.farma.2011.05.002_bib0185","first-page":"234","article-title":"FLAG-IDA in the treatment of refractory\/relapsed acute leukaemias: single centre study","volume":"55","author":"Hashmi","year":"2005","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.farma.2011.05.002_bib0190","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0145-2126(02)00003-6","article-title":"FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies","volume":"26","author":"De la Rubia","year":"2002","journal-title":"Leuk Res"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634311002030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634311002030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:16:45Z","timestamp":1761106605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634311002030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1130634311002030"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2011.05.002","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad y seguridad del r\u00e9gimen FLAG-IDA en leucemias agudas resistentes o recidivantes","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2011.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 SEFH. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}